Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides

Biochimica et Biophysica Acta - Gene Structure and Expression

Volumn 1489, Issue 1, 1999, Pages 53-67

  Agrawal, Sudhir ^a  

^a HYBRIDON INC   (United States)

Author keywords

Antisense; Antiviral; CpG; Immune stimulation; Mixed backbone oligonucleotide; Oligonucleotide; Pharmacokinetics; Pro drug

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; OLIGONUCLEOTIDE; POLYANION; PRODRUG; TRECOVIRSEN;

ANIMAL EXPERIMENT; BLOOD CLOTTING DISORDER; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG DESIGN; DRUG SAFETY; DRUG STRUCTURE; HUMAN; IMMUNOSTIMULATION; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; REVIEW; THROMBOCYTOPENIA; TISSUE DISTRIBUTION;

ANIMALS; BASE SEQUENCE; CPG ISLANDS; DRUG DESIGN; DRUG STABILITY; GENE EXPRESSION; HAPLORHINI; HUMANS; MICE; NUCLEIC ACID HETERODUPLEXES; OLIGONUCLEOTIDES, ANTISENSE; POLYMERS; RATS; SUBSTRATE SPECIFICITY; THIONUCLEOTIDES; TISSUE DISTRIBUTION;

EID: 0032700356     PISSN: 01674781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-4781(99)00141-4     Document Type: Review

References (111)

1. Zamecnik P.C., Stephenson M.L. Inhibition of Rous sarcoma virus replication and transformation by a specific oligonucleotide. Proc. Natl. Acad. Sci. USA. 75:1978;280-284.
2. P.C. Zamecnik, History of antisense oligonucleotides, in: S. Agrawal (Ed.), Antisense Therapeutics, Humana Press, Totowa, NJ, 1996, pp. 1-11.
3. S. Agrawal, Antisense Therapeutics, Humana Press, Totowa, NJ, 1996.
4. Ciba Foundation Symposium, Oligonucleotides as Therapeutic Agents, John Wiley and Sons, New York, 1997.
5. S. Crooke (Ed.), Antisense Research and Application, Springer, New York, 1998.
6. E. Wickstrom (Ed.), Clinical Trials of Genetic Therapy with Antisense DNA and DNA Vectors, Marcel Dekker, New York, 1998.
7. C.A. Stein, A.M. Kreig (Eds.), Applied Antisense Oligonucleotide Technology. Wiley-Liss, New York, 1998.
8. Agrawal S. Antisense oligonucleotides: towards clinical trials. Trends Biotechnol. 14:1996;376-387.
9. Akhtar S., Agrawal S. In vivo studies with antisense oligonucleotides. Trends Pharm. Sci. 18:1997;12-18.
10. Bennett C.F. Antisense oligonucleotides: is the glass half full, or half empty? Biochem. Pharmacol. 55:1998;9-19.
11. Agrawal S., Zhao Q. Antisense therapeutics. Curr. Opin. Chem. Biol. 2:1998;519-528.
12. Branch A.D. A good antisense molecule is hard to find. Trends Pharmacol. Sci. 23:1998;39-50.
13. Gerwirtz A.M., Sokol D.L., Ratajczak M.Z. Nucleic acid therapeutics: state of the art and future prospects. Blood. 92:1988;712-736.
14. Agrawal S., Goodchild J., Civiera M.P., Thorton A.H., Sarin P.S., Zamecnik P.C. Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus. Proc. Natl. Acad. Sci. USA. 85:1988;7079-7083.
15. Matsukura M., Zon G., Shinozuka K., Robert-Guroff M., Shimada T., Stein C.A., Mitsuya H., Wong-Staal F., Cohen J.S., Broder S. Regulation of viral expression of human immunodeficiency virus in in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells. Proc. Natl. Acad. Sci. USA. 86:1989;4244.
16. Agrawal S., Ikeuchi T., Sun D., Sarin P.S., Konopka A., Maizel T., Zamecnik P.C. Inhibition of human immunodeficiency virus in early infected and chronically infected cells by antisense oligodeoxynucleotides and their phosphorothioate analogues. Proc. Natl. Acad. Sci. USA. 86:1989;7790-7794.
17. Agrawal S., Tang J.Y., Sun D., Sarin P.S., Zamecnik P.C. Synthesis and anti-HIV activity of oligoribonucleotides and their phosphorothioate analogs, Antisense Strategies. Ann. NY Acad. Sci. 660:1992;2-10.
18. Lisziewicz J., Sun D., Klotman M., Agrawal S., Zamecnik P.C., Gallo R. Specific inhibition of human immunodeficiency virus type I replication by antisense oligonucleotides: an in vitro model for treatment. Proc. Natl. Acad. Sci. USA. 89:1992;11209-11213.
19. Lisziewicz J., Sun D., Metelev V., Zamecnik P., Gallo R., Agrawal S. Long-term treatment of human immunodeficiency virus-infected cells with antisense oligonucleotide phosphorothioates. Proc. Natl. Acad. Sci. USA. 90:1993;3860-3864.
20. Lisziewicz J., Sun D., Weichold F.F., Thierry A.R., Lusso P., Tang J., Gallo R.C., Agrawal S. Antisense oligodeoxynucleotide phosphorothioate complementary to gag mRNA blocks replication of human immunodeficiency virus type 1 in human peripheral blood cells. Proc. Natl. Acad. Sci. USA. 91:1994;7942-7946.
21. Yamaguchi K., Papp B., Zhang D., Ali A.N., Agrawal S., Byrn R.A. The multiple inhibitory mechanism of GEM91, a Gag antisense phosphorothioate oligonucleotide, for human immunodeficiency virus type-1. AIDS Res. Hum. Retroviruses. 13:1997;545-554.
22. Veal G.J., Agrawal S., Byrn R.A. Sequence specific RNaseH cleavage of gag mRNA from HIV-1 infected cells by an antisense oligonucleotide. Nucleic Acids Res. 26:1998;5670-5675.
23. Stein C.A., Mtsukura M., Subasinghe C., Brode S., Cohen J.S. Phosphorothioate oligodeoxynucleotides are potent sequence nonspecific inhibitors of de novo infection by HIV. AIDS Res. Hum. Retroviruses. 5:1989;639.
24. +. J. AIDS. 4:1991;686-693.
25. Zelphati O., Imbach J.L., Signoret N., Zon G., Rayner B., Leserman L. Antisense oligonucleotides in solution or encapsulated in immunoliposomes inhibit replication of HIV-1 by several different mechanisms. Nucleic Acids Res. 22:1994;4307.
26. S. Agrawal, J. Temsamani, Oligonucleotides as antiviral agents, in: K.H. Schlingensiepen (Ed.), Antisense Oligonucleotides: From Technology to Therapy, Blackwell, Berlin, 1996, pp. 225-250.
27. Guvakova M.A., Yakubov L.A., Vlodavsky I., Tonkinson J.L., Stein C.A. Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibits its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J. Biol. Chem. 270:1995;2620-2627.
28. Burgess T.L., Fisher E.F., Ross S.L., Bready J.V., Qian Y., Bayewitch L.A., Cohen A.M., Herra C.J., Hu S.S.-F., Kramer T.B., Lott F.D., Martin F.H., Pierce G.F., Simonec L., Farrell C.L. The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc. Natl. Acad. Sci. USA. 92:1995;4051-4055.
29. Dean N.M., McKay R. Inhibition of protein kinase C α expression in mince after systemic administration of phosphorothioate antisense oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA. 91:1994;11762-11766.
30. Masood R., Cai J., Zheng T., Smith D.L., Naidu Y., Gill P.S. Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-kaposi sarcoma. Proc. Natl. Acad. Sci. USA. 94:1997;979.
31. Monia B.P., Johnston J.F., Geiger T., Muller M., Fabbro D. Antitumor activity of a phosphorothioate oligodeoxynucleotide targeted against C-raf kinase. Nat. Med. 2:1995;668-675.
32. Giles R.V., Spiller D.G., Tidd D.M. Detection of ribonuclease H-generated mRNA fragments in human leukemia cells following reversible membrane permeabilization in the presence of antisense oligodeoxynucleotides. Antisense Res. Dev. 5:1995;23-31.
33. Kumasaka T., Quinlan W.M., Doyle N.A., Condon T.P., Sligh J., Takei F., Beaudet A.L., Bennett C.F., Doerschuk C.M. The role of the intercellular adhesion molecule-1 (ICAM-1) in endotoxin-induced pneumonia evaluated using ICAM-1 antisense oligonucleotides, anti-ICAM-1 monoclonal antibodies, and ICAM-1 mutant mice. J. Clin. Invest. 97:1996;2362-2369.
34. Nestcrova M., Cho-Chung Y.S. A single-injection protein kinase A-directed antisense treatment to inhibit tumor growth. Nat. Med. 1:1995;528-533.
35. Maran A., Waller C.F., Paranjape J.M., Li G., Xiao W., Zhang K., Kalaycio M.E., Maitra R.K., Lichtin A.E., Brugger W., Torrence P.F., Silverman R.H. 2′,5′-Oligoadenylate-antisense chimeras cause RNase L to selectively degrade bcr/abl mRNA in chronic myelogenous leukemia cells. Blood. 91:1998;4336-4343.
36. Sierakowska H., Sambade M.J., Agrawal S., Kole R. Repair of thalassemic human β-globulin mRNA in mammalian cells by antisense oligonucleotides. Proc. Natl. Acad. Sci. USA. 93:1996;12840-12844.
37. Chen L., Agrawal S., Zhou W., Zhang R., Chen J. Synergistic activation of p53 by inhibition of mdm2 expression and DNA damage. Proc. Natl. Acad. Sci. USA. 95:1998;195-200.
38. Wurl P., Meye A., Schmidt H., Lautenschlager C., Kalthoff H., Path F.W., Taubert H. High prognostic significance of mdm2/p53 co-overexpression in soft tissue sarcomas of extremities. Oncogene. 16:1998;1183-1185.
39. Watanabe T., Hotta T., Ichikawa A., Kinoshita T., Nagai H., Uchida T., Murate T., Saito H. The mdm2 oncogene over-expression in chronic lymphocytic leukemia and low grade lymphoma of B cell origin. Blood. 84:1994;3158-3165.
40. Branda R.F., Moore A.L., Mathews L., McCormack J.J., Zon G. Immune stimulation by an antisense oligo complementary to the rev gene of HIV-1. Biochem. Pharmacol. 45:1993;2037-2043.
41. Kreig A.M., Yi A.E., Matson S., Waldschmidt T.J., Bishop G.A., Teasdale R., Koretzky G.A., Klinman D.M. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 374:1995;546-549.
42. Zhao Q., Temsamani J., Iadarola P.L., Jiang Z.W., Agrawal S. Effect of different chemically modified oligodeoxynucleotides on immune stimulation. Biochem. Pharmacol. 51:1996;173-182.
43. Klinman D.M., Yi A., Beaucage S.L., Conover J., Kreig M.A. CpG motifs expressed by bacterial DNA rapidly induced lymphocytes to secret IL-6, Il-12 and IFN-gamma. Proc. Natl. Acad. Sci. USA. 93:1996;2879-2883.
44. Pisetsky D.S. Immune activation by bacterial DNA: a new genetic code. Immunity. 5:1996;303-310.
45. Zhao Q., Temsamani J., Zhou R., Agrawal S. Pattern and kinetics of cytokines production following administration of phosphorothioate oligonucleotides in mice. Antisense Nucleic Acid Drug Dev. 79:1997;495-502.
46. Perez J.R., Li Y., Stein C.A., Majumder S., van Oorschot A., Narayanan R. Sequence-independent induction of Sp1 transcription factor activity by phosphorothioate oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA. 91:1994;5957-5961.
47. P.J. Dunford, M.J. Mulqueen, S. Agrawal, Non-specific oligonucleotides containing CpG motifs protect against lethal viral infections in mice, Antisense 97: Targeting the Molecular Basis of Disease, Cambridge, MA, USA, 1997 (abstract).
48. Moldoveanu Z., Love-Homan L., Huang W.Q., Kreig A.M. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine. 16:1998;1216-1224.
49. Wooldrige J.E., Ballas Z., Kreig A.M., Weiner G.J. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood. 89:1997;2994-2998.
50. Krieg A.M., Love-Homan L., Yi A.K., Harty J.T. CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J. Immunol. 161:1998;2428-2434.
51. Agrawal S., Temsamani J., Tang J.Y. Pharmacokinetics, biodistribution and stability of oligodeoxynucleotide phosphorothioates in mice. Proc. Natl. Acad. Sci. USA. 88:1991;7595-7599.
52. Agrawal S., Temsamani J., Galbraith W., Tang J.Y. Pharmacokinetics of antisense oligonucleotides. Clin. Pharmacokinet. 28:1995;7-16.
53. Temsamani J., Tang J.Y., Agrawal S. Capped oligodeoxynucleotide phosphorothioates: pharmacokinetics and stability in mice Antisense Strategies. Ann. NY Acad. Sci. 660:1992;318-320.
54. Temsamani J., Roskey A., Chaix C., Agrawal S. In vivo metabolic profile of a phosphorothioate oligodeoxyribonucleotide Antisense and Nucleic Acid Drug. Development. 7:1997;159-165.
55. Zhang R., Diasio R.B., Lu Z., Liu T., Jiang Z., Galbraith W.M., Agrawal S. Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1. Biochem. Pharmacol. 49:1995;929-939.
56. Grindel J.M., Musick T.J., Jiang Z., Roskey A., Agrawal S. Pharmacokinetics and metabolism of an oligonucleotide phosphorothioate (GEM91) in cynomolgus monkeys following intravenous infusion. Antisense Nucleic Acids Drug Dev. 8:1998;43-52.
57. Zhang R., Yan J., Shahinian H., Amin G., Lu Z., Liu T., Saag M., Jiang Z., Temsamani J., Martin R., Schechter P., Agrawal S., Diasio R. Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM91) in HIV-infected subjects. Clin. Pharmacol. Exp. Ther. 58:1995;44-53.
58. Crooke S.T., Graham M.J., Zuckerman J.E., Brooks D., Conklin B.S., Cummins L.L., Greig M.J., Guinosso C.J., Kornbrust D., Manoharan M., Sasmor H.M., Schlich T., Tivel K.L., Griffey R.H. Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J. Pharmacol. Exp. Ther. 277:1996;923-937.
59. Agrawal S., Tan W., Cai Q., Xie X., Zhang R. In vivo pharmacokinetics of phosphorothioate oligonucleotides containing contiguous guanosines. Antisense Nucleic Acid Drug Dev. 7:1997;245-249.
60. Agrawal S., Zhao Q., Jiang Z., Oliver C., Giles H., Heath J., Serota D. Toxicological effects of a oligonucleotide phosphorothioate and its analogs following intravenous administration in rats. Antisense Nucleic Acids Drug Dev. 7:1997;575-584.
61. Henry S.P., Montheith D., Levin A.A. Antisense oligonucleotide inhibitors for the treatment of cancer: 2. Toxicological properties of phosphorothioate oligodeoxynucleotides. Anticancer Drug. 12:1997;395-408.
62. Galbraith W.M., Hobson W.C., Giclas P.C., Schechter P.J., Agrawal S. Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res. Dev. 4:1994;201-206.
63. Henry S.P., Leeds J., Giclass P.S.C., Gillett N.A., Pribble J.P., Kornbrust D.J., Levin A.A. The toxicity of ISIS 3521, a phosphorothioate oligonucleotide, in a 4-week study in cynomolgus monkeys. Toxicology. 120:1997;145-155.
64. Agrawal S., Iadorola P.L., Temsamani J., Zhao Q., Shaw D. Effect of G-rich sequences on the synthesis, purification, binding, cell uptake, and hemolytic activity of oligonucleotides. Bioorgan. Med. Chem. Lett. 6:1996;2219-2224.
65. P.J. Schechter, R.R. Martin, Safety and tolerance of phosphorothioate in humans, in: S. Crooke (Ed.), Antisense Research and Application, Springer, New York, 1998, pp. 233-241.
66. B.I. Sikic, A.R. Yuen, J. Advani, J. Halsey, G.A. Fisher, A. Holmlund, A. Dorr, Antisense oligonucleotide therapy targeted to protein kinase C-α (ISIS 3521/CGP 6412A) by 21 day infusion: results of the phase I trial and activity in ovarian carcinomas, American Society of Clinical Oncology, 34th Annual Meeting, Los Angeles, CA, 1998, Abstract 1654.
67. Glover J.M., Leeds J.M., Mant T.G., Amin D., Kisner D.L., Zuckerman J.E., Geary R.S., Levin A.A., Shanahan W.R. Jr. Phase I safety and pharmacokinetic profile of an intracellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302). J. Pharmacol. Exp. Ther. 283:(3):1997;1173-1180.
68. Bergan R., Connell Y., Fahmy B., Kyle E., Neckers L. Aptameric inhibition of p210bcr-abl tyrosine kinase autophosphorylation by oligodeoxynucleotides of defined sequence and backbone structure. Nucleic Acids Res. 22:(11):1994;2150-2154.
69. Kreig A.M., Matson S., Cheng S., Fisher E., Koretzky G.A., Koland J.G. Identification of an oligodeoxynucleotides sequence motif that specifically inhibits phosphorylation by protein tyrosine kinases. Antisense Nucleic Acid Drug Dev. 7:(2):1997;115-123.
70. Agrawal S., Iyer R.P. Modified oligonucleotides as therapeutic and diagnostic agents. Curr. Opin. Biotechnol. 6:1995;12-19.
71. Agrawal S., Rustagi P.K., Shaw D.R. Novel enzymatic and immunological responses to oligonucleotides. Toxicol. Lett. 82/83:1995;431-434.
72. Shaw D.R., Rustagi P.K., Kandimalla E.R., Manning A.M., Jiang Z., Agrawal S. Effects of synthetic oligonucleotides on human complement and coagulation. Biochem. Pharmacol. 53:1997;1123-1132.
73. Kandimalla E.R., Shaw D.R., Agrawal S. Effects of phosphorothioate oligodeoxyribonucleotide and oligoribonucleotide on human complement and coagulation. Bioorgan. Med. Chem. Lett. 8:1998;2102-2108.
74. Tang J.Y., Roskey A., Li Y., Agrawal S. Enzymatic synthesis of stereoregular (all Rp) oligonucleotide phosphorothioate and its properties. Nucleosides Nucleotides. 14:1995;985-989.
75. Buczko W., Ierneiwski C., Kobylanska A., Koziolkiewicz M., Okruszek A., Pawlowska Z., Pluskota E., Stec W. Modulation of plasminogen activator inhibitor type-1 biosynthesis in vitro and in vivo with oligo (nucleoside phosphorothioate)s and related constructs. Pharmacol. Ther. 76:1997;161-195.
76. Iyer R.P., Guo M.J., Yu D., Agrawal S. Solid-phase stereo-selective synthesis of oligonucleotide phosphorothioates: the nucleoside bicyclic oxazaphospholidines as novel synthons. Tetrahedron Lett. 39:1998;2491-2494.
77. Guo M., Yu D., Iyer R.P., Agrawal S. Solid-phase stereo-selective synthesis of 2′-O-methyloligoribonucleoside phosphorothioates using nucleoside bicyclic oxazaphospholidines. Bioorgan. Med. Chem. Lett. 8:1998;2539-2544.
78. Metelev V., Lisziewicz J., Agrawal S. Study of antisense oligonucleotide phosphorothioates containing segments of 2′-O-methyloligoribonucleotides. Bioorgan. Med. Chem. Lett. 4:1994;2929-2934.
79. Yu D., Iyer R.P., Shaw D.R., Lisziewicz J., Li Y., Jiang Z., Roskey A., Agrawal S. Hybrid oligonucleotides: synthesis, biophysical properties, stability studies and biological activity. Bioorgan. Med. Chem. 4:1996;1685-1692.
80. Shen L.X., Kandimalla E.R., Agrawal S. Impact of mixed-backbone oligonucleotides on target binding affinity and target cleaving specificity and selectivity by E. Coli RNase H. Bioorgan. Med. Chem. 6:1998;695-1705.
81. Agrawal S., Mayrand S.M., Zamecnik P.C., Pederson T. Site specific excision from RNA by RNase H and mixed phosphate backbone oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA. 87:1990;1401-1405.
82. Agrawal S., Jiang Z., Zhao Q., Shaw D.R., Saxinger C. Mixed-backbone oligonucleotides containing phosphorothioate and methylphosphonate linkages as second-generation antisense oligonucleotides. Nucleosides Nucleotides. 16:1997;927-936.
83. Agrawal S., Jiang Z., Zhao Q., Shaw D., Cai Q., Roskey A., Channavajjala L., Saxinger C., Zhang R. Mixed-backbone oligonucleotides as second-generation antisense oligonucleotides: in vitro and in vivo studies. Proc. Natl. Acad. Sci. USA. 94:1997;2620-2625.
84. Hacker H., Mischak H., Miethke T., Liptay S., Schmid R., Sparwasser T., Heeg K., Lipford G.B., Wagner H. CpG-DNA-specific activation of antigen-presenting cells requires stress kinase and is preceded by non-specific endocytosis and endosomal maturation. EMBO J. 17:(21):1998;6230-6240.
85. Yi A.K., Krieg A.M. Rapid induction of mitogen-activated protein kinase by immune stimulatory CpG DNA. J. Immunol. 161:(9):1998;4493-4497.
86. Agrawal S., Goodchild J. Oligodeoxynucleotide methyl-phosphonate: synthesis and enzyme degradation. Tetrahedron Lett. 28:(31):1987;3539-3542.
87. Agrawal S. Antisense oligonucleotides as antiviral agents. Trends Biotechnol. 10:1992;152-158.
88. Devlin T., Iyer R.P., Johnson S., Agrawal S. Mixed-backbone oligonucleotides containing internucleotidic primary phosphoramidate linkages. Bioorgan. Med. Chem. Lett. 6:1996;2663-2668.
89. Padmapriya A.A., Agrawal S. Synthesis of oligodeoxynucleoside methylphosphonothioates. Bioorgan. Med. Chem. Lett. 3:1993;761-764.
90. Iyer R.P., Yu D., Jiang Z., Agrawal S. Synthesis, biophysical properties and stability studies of mixed backbone oligonucleotides containing segments of methyphosphotriester internucleotide linkages. Tetrahedron. 52:1996;1853-1859.
91. Habus I., Agrawal S. Oligonucleotides containing acyclic nucleoside analogues with carbamate internucleoside linkages. Nucleosides Nucleotides. 14:1995;1853-1859.
92. Kandimalla R., Temsamani J., Agrawal S. Synthesis and properties of 2′-O-methylribonucleotide methylphosphonate containing chimeric oligonucleotides. Nucleosides Nucleotides. 14:(3-5):1995;1031-1035.
93. M. Guo, D. Yu, S. Agrawal, Mixed-backbone oligonucleotides containing segments of deoxynucleosides phosphorothioate and 2′-O-methyribonucleosides methylphosphonate: synthesis and properties, Phosphorus, Sulfur, Silicon and Related Elements (1999) in press.
94. Kandimalla E.R., Manning A., Zhao Q., Shaw D.R., Byrn R.A., Sasisekharan V., Agrawal S. Mixed-backbone antisense oligonucleotides: design, biochemical and biological properties of oligonucleotides containing 2′-5′-ribo- and 3′-5′-deoxyribonucleotide segments. Nucleic Acids Res. 25:(2):1997;370-378.
95. Zhang R., Lu Z., Liu T., Zhao H., Zhang X., Diasio R., Habus I., Jiang Z., Iyer R.P., Yu D., Agrawal S. In vivo stability, disposition and metabolism of a 'hybrid' oligonucleotide phosphorothioate in rats. Biochem. Pharmacol. 50:(4):1995;545-556.
96. Agrawal S., Zhang X., Zhao H., Lu Z., Yan J., Cai H., Diasio R.B., Habus I., Jiang Z., Iyer R.P., Yu D., Zhang R. Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration. Biochem. Pharmacol. 50:1995;571-576.
97. S. Agrawal, R. Zhang, Pharmacokinetics and bioavailability of oligonucleotides following oral and colorectal administration in experimental animals, in: S.T. Crooke (Ed.), Antisense Research and Application, Handbook of Experimental Pharmacology, Springer, Berlin, 1998, pp. 525-543.
98. Agrawal S., Zhao Q. Mixed backbone oligonucleotides: improvement in oligonucleotide-induced toxicity in vivo. Antisense Nucleic Acid Drug Dev. 8:(2):1998;135-139.
99. H. Chen, Phase I Evaluation of GEM 231, a second generation oligonucleotide targeted at type 1 protein kinase A (PKA-1) in patients with refractory solid tumors, Antisense 98, organized by Nature Biotechnology, October 1998, abstract.
100. Altmann K.H., Dean N.M., Fabbro D., Freier S.M., Geiger T., Haner R., Husken D., Martin P., Monia B.P., Muller M., Natt F., Nicklin P., Phillips J., Pieles U., Sasmor H., Moser H.E. Second generation of antisense oligonucleotides: From nuclease resistance to biological efficacy in animals. Chimia. 50:1996;168-176.
101. Zhou W., Agrawal S. Mixed-backbone oligonucleotides as second generation antisense agents with reduced phosphorothioate related side effects. Bioorgan. Med. Chem. Lett. 8:1998;3269-3274.
102. Tang J.Y., Temsamani J., Agrawal S. Self-stabilized antisense oligonucleotide phosphorothioates: synthesis, properties and anti-HIV activity. Nucleic Acids Res. 20:1993;2729-2735.
103. S. Agrawal, J. Temsamani, J.-Y. Tang, Self-stabilized oligonucleotides as novel antisense agents, in: A. Saghir (Ed.), Delivery Strategies for Antisense Oligonucleotide Therapeutics, CRC Press, 1995, pp. 105-121.
104. Zhang R., Lu Z., Zhang X., Diasio R., Liu T., Jiang Z., Agrawal S. In vivo stability and disposition of a self-stabilized oligodeoxynucleotide phosphorothioate in rats. Clin. Chem. 41:1995;836-843.
105. Iyer R.P., Yu D., Agrawal S. Prodrugs of oligonucleotides: the acyloxyalkyl esters of oligodeoxyribonucleoside phosphorothioates. Bioorgan. Chem. 23:1995;1-21.
106. Iyer R., Yu D., Devlin T., Ho N., Agrawal S. Axyloxyaryl prodrugs of oligonucleotide phosphorothioates. Bioorgan. Med. Chem. Lett. 6:1996;1917-1922.
107. Iyer R.P., Ho N.H., Yu D., Agrawal S. Bioreversible oligonucleotide conjugates by site-specific derivatization. Bioorgan. Med. Chem. Lett. 7:1997;871-876.
108. Agrawal S., Zhang X., Cai Q., Kandimalla E.R., Manning A., Jiang Z., Marcel T., Zhang R. Effect of aspirin on protein binding and tissue disposition of oligonucleotides phosphorothioate in rats. J. Drug Targeting. 5:1998;303-312.
109. S. Agrawal, In vivo pharmacokinetics of oligonucleotides, in: C.Y. Stein, A.M. Krieg (Eds.) Applied Antisense Oligonucleotide Technology, John Wiley and Sons, New York, 1998, pp. 365-385.
110. Agrawal S., Zhang R. Pharmacokinetics of oligonucleotides, oligonucleotides as therapeutic agents. CIBA Found. Symp. Ser. 209:1997;60-75.
111. S. Agrawal, R. Zhang, Pharmacokinetics of phosphorothioate oligonucleotides and its novel analogs, in: B. Weiss (Ed.), Antisense Oligodeoxynucleotides and Antisense RNA as Novel Pharmacological and Therapeutic Agents, CRC Press, 1997, pp. 57-78.